Piperacillin + Tazobactam Uses, Dosage, Side Effects & Price | DrugsAtlas
Authoritative Clinical Reference
Navigation
Therapeutic Class
Antibacterial
Subclass
Extended-spectrum penicillin + Beta-lactamase inhibitor combination
Speciality
Infectious Disease
Schedule (India)
Schedule H
Routes
Intravenous (IV)
Formulations
| Form | Strengths (Piperacillin + Tazobactam) |
|---|---|
| Powder for IV Injection/Infusion | 4 g + 500 mg (4.5 g vial) |
| Powder for IV Injection/Infusion | 2 g + 250 mg (2.25 g vial) |
| Powder for IV Injection/Infusion | 1 g + 125 mg (1.125 g vial) — limited availability |
Reconstitution Note: Reconstitute with Sterile Water for Injection, Normal Saline, or 5% Dextrose. Administer as IV infusion over 30 minutes (standard) or 3–4 hours (extended infusion for severe infections).
Adult indications
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
1. Nosocomial Pneumonia (Including Ventilator-Associated Pneumonia)
Adults:
| Parameter | Recommendation |
|---|---|
| Starting dose | 4.5 g IV every 8 hours |
| Titration | Increase frequency to every 6 hours for severe infections or high bacterial load |
| Usual maintenance dose | 4.5 g IV every 6–8 hours |
| Maximum dose | 4.5 g IV every 6 hours (18 g piperacillin/day) |
| Duration | 7–14 days; guided by clinical response and cultures |
Clinical Note: Combine with aminoglycoside or fluoroquinolone for suspected Pseudomonas aeruginosa infection. Not effective against MRSA — add vancomycin/linezolid if suspected.
2. Complicated Intra-Abdominal Infections (cIAI)
Adults:
| Parameter | Recommendation |
|---|---|
| Starting dose | 4.5 g IV every 8 hours |
| Titration | Increase to every 6 hours for severe peritonitis or sepsis |
| Usual maintenance dose | 4.5 g IV every 6–8 hours |
| Maximum dose | 4.5 g IV every 6 hours |
| Duration | 4–7 days following adequate source control; extend if source control incomplete |
Clinical Note: Provides coverage for gram-negative aerobes, gram-positive organisms, and anaerobes. Adequate surgical source control is essential.
3. Complicated Urinary Tract Infections (cUTI) / Pyelonephritis
Adults:
| Parameter | Recommendation |
|---|---|
| Starting dose | 4.5 g IV every 8 hours |
| Titration | Not routinely required |
| Usual maintenance dose | 4.5 g IV every 8 hours |
| Maximum dose | 4.5 g IV every 6 hours (in severe urosepsis) |
| Duration | 7–14 days; step-down to oral therapy when clinically stable |
4. Complicated Skin and Soft Tissue Infections (Including Diabetic Foot Infections)
Adults:
| Parameter | Recommendation |
|---|---|
| Starting dose | 4.5 g IV every 8 hours |
| Titration | Increase to every 6 hours for severe necrotising infections |
| Usual maintenance dose | 4.5 g IV every 6–8 hours |
| Maximum dose | 4.5 g IV every 6 hours |
| Duration | 7–14 days for soft tissue infections; 2–4 weeks for osteomyelitis component in diabetic foot |
Clinical Note: Add MRSA coverage (vancomycin/linezolid) if risk factors present. Surgical debridement critical for necrotising infections.
5. Febrile Neutropenia (Empirical Therapy in High-Risk Patients)
Adults:
| Parameter | Recommendation |
|---|---|
| Starting dose | 4.5 g IV every 6 hours |
| Titration | Not applicable |
| Usual maintenance dose | 4.5 g IV every 6 hours |
| Maximum dose | 4.5 g IV every 6 hours |
| Duration | Until neutrophil recovery (ANC >500/µL) and afebrile for ≥48 hours; minimum 7 days |
Clinical Note: Preferred empirical monotherapy for febrile neutropenia per AIIMS and Tata Memorial protocols. Add aminoglycoside if septic shock or suspected resistant Pseudomonas. Add vancomycin if catheter-related infection or skin/soft tissue focus suspected.
6. Sepsis / Septic Shock (Empirical Therapy for Healthcare-Associated Infections)
Adults:
| Parameter | Recommendation |
|---|---|
| Starting dose | 4.5 g IV every 6 hours |
| Titration | Not applicable |
| Usual maintenance dose | 4.5 g IV every 6 hours |
| Maximum dose | 4.5 g IV every 6 hours |
| Duration | 7–14 days; de-escalate based on culture results |
Clinical Note: Appropriate for suspected gram-negative sepsis including ESBL-producers (if local susceptibility >90%). Consider extended infusion (4 hours) for severe sepsis to optimise pharmacodynamics.
Secondary Indications — Adults (Off-label, if any)
| Indication | Dose | Duration | Notes |
|---|---|---|---|
| Severe Community-Acquired Pneumonia (CAP) requiring ICU admission | 4.5 g IV every 6 hours | 7–10 days | OFF-LABEL. Used when aspiration suspected or healthcare-associated risk factors present. Add macrolide for atypical coverage. Based on institutional protocols (AIIMS, PGI) |
| Pyelonephritis with suspected ESBL organisms | 4.5 g IV every 8 hours | 10–14 days | OFF-LABEL. Specialist use. Requires local antibiogram data showing susceptibility. Step-down to oral per culture |
| Cholangitis / Hepatobiliary Sepsis | 4.5 g IV every 6–8 hours | 7–10 days with source control | OFF-LABEL. Provides broad coverage including anaerobes. ERCP/drainage essential |
Paediatric indications
PAEDIATRIC DOSING (Specialist Only)
Primary Indications (Approved / Standard in India)
1. Nosocomial Pneumonia / Complicated Intra-Abdominal Infections / Complicated Skin and Soft Tissue Infections
Weight-Based Dosing (≥2 months to <40 kg):
| Parameter | Recommendation |
|---|---|
| Starting dose | 80 mg/kg (piperacillin component) IV |
| Titration | May increase to 100 mg/kg/dose for severe infections |
| Usual maintenance dose | 80–100 mg/kg (piperacillin component) every 6–8 hours |
| Maximum single dose | 4 g piperacillin (4.5 g Pip-Tazo) |
| Maximum daily dose | 16 g piperacillin/day (300–400 mg/kg/day) |
| Duration | As per indication; typically 7–14 days |
Dosing Table by Weight:
| 5 kg | 400–500 mg (Pip component) | Every 8 hours |
|---|---|---|
| 10 kg | 800–1000 mg (Pip component) | Every 8 hours |
| 20 kg | 1.6–2 g (Pip component) | Every 6–8 hours |
| 30 kg | 2.4–3 g (Pip component) | Every 6–8 hours |
| ≥40 kg | Adult dosing (4.5 g) | Every 6–8 hours |
2. Febrile Neutropenia (Empirical Therapy)
Children ≥2 months:
| Parameter | Recommendation |
|---|---|
| Starting dose | 80–100 mg/kg (piperacillin component) IV |
| Titration | Not applicable |
| Usual maintenance dose | 80–100 mg/kg every 6 hours |
| Maximum single dose | 4.5 g |
| Maximum daily dose | 18 g piperacillin/day |
| Duration | Until ANC recovery and afebrile ≥48 hours |
Clinical Note: Preferred empirical monotherapy for paediatric febrile neutropenia at major oncology centres. Add aminoglycoside if haemodynamically unstable.
3. Sepsis / Severe Bacterial Infections
Neonates (Specialist supervision mandatory):
| Age | Dose (Piperacillin component) | Frequency |
|---|---|---|
| <7 days, <2 kg | 50 mg/kg | Every 12 hours |
| <7 days, ≥2 kg | 50 mg/kg | Every 8 hours |
| 7–28 days, <2 kg | 50 mg/kg | Every 8 hours |
| 7–28 days, ≥2 kg | 50 mg/kg | Every 6 hours |
Secondary Indications — Paediatrics (Off-label, if any)
| Indication | Dose | Duration | Notes |
|---|---|---|---|
| Cystic Fibrosis Pulmonary Exacerbations | 90–100 mg/kg (Pip component) every 6 hours | 14–21 days | OFF-LABEL. Specialist only. Anti-pseudomonal coverage required. Maximum 18 g/day |
Age Restrictions and Safety Monitoring
| Age Group | Recommendation |
|---|---|
| <2 months | Not recommended except under specialist supervision in NICU setting |
| 2 months–12 years | Weight-based dosing; requires paediatric infectious disease input for complex infections |
| ≥12 years and ≥40 kg | Adult dosing appropriate |
Safety Monitoring in Paediatrics:
- Renal function monitoring (serum creatinine)
- Electrolytes (particularly potassium)
- CBC with differential if therapy >7 days
- Signs of hypersensitivity or infusion reactions
- Monitor IV site for phlebitis
Renal Adjustments
Dose adjustment required based on creatinine clearance:
| CrCl (mL/min) | Dose Recommendation |
|---|---|
| >40 | 4.5 g IV every 6–8 hours (no adjustment) |
| 20–40 | 4.5 g IV every 8 hours |
| <20 | 2.25 g IV every 8 hours |
| Haemodialysis | 2.25 g IV every 8 hours + supplemental dose of 2.25 g after each dialysis session |
| CAPD | 2.25 g IV every 12 hours |
| CRRT (CVVH/CVVHD/CVVHDF) | 4.5 g IV every 8 hours (adjust based on effluent rate and clinical response) |
Clinical Note: Calculate CrCl using Cockcroft-Gault formula. In elderly patients, serum creatinine may underestimate renal impairment.
Hepatic adjustment
Contraindications
- Known hypersensitivity to piperacillin, tazobactam, or any penicillin
- History of severe hypersensitivity reaction (anaphylaxis, angioedema) to any beta-lactam antibiotic (penicillins, cephalosporins, carbapenems)
- History of cholestatic jaundice or hepatic dysfunction associated with piperacillin-tazobactam use
Cautions
- History of non-severe penicillin or cephalosporin allergy — monitor closely for allergic reactions (cross-reactivity risk 1–2%)
- Renal impairment — dose adjustment essential to prevent drug accumulation, neurotoxicity, and seizures
- Pre-existing seizure disorder — high doses may lower seizure threshold; maintain appropriate dosing for renal function
- Concurrent nephrotoxic agents (aminoglycosides, vancomycin, NSAIDs, amphotericin B) — monitor renal function closely
- History of Clostridioides difficile infection or antibiotic-associated colitis
- Sodium load — each 4.5 g vial contains approximately 216 mg (9.4 mEq) sodium; use cautiously in patients with heart failure, cirrhosis, or sodium restriction
- Bleeding disorders or concurrent anticoagulation — may prolong bleeding time
- Prolonged therapy (>14 days) — increased risk of superinfection, haematological abnormalities
Pregnancy
| Parameter | Recommendation |
|---|---|
| Overall safety | Generally considered safe; widely used in pregnancy for severe infections |
| Risk category | Category B (US legacy); no formal India classification |
| Preferred alternatives | None required for severe infections; Pip-Tazo preferred when broad-spectrum IV coverage needed |
| When to use | Appropriate for serious infections including pyelonephritis, chorioamnionitis, postpartum sepsis |
| Monitoring | Maternal renal function, LFTs in prolonged courses; standard foetal monitoring |
Lactation
| Parameter | Recommendation |
|---|---|
| Compatibility | Compatible with breastfeeding |
| Drug levels in milk | Low; minimal systemic absorption by infant expected |
| Preferred alternatives | None required; acceptable during breastfeeding |
| Infant monitoring | Observe for loose stools, oral thrush, or rash; temporary GI disturbance possible but usually mild |
Elderly
| Parameter | Recommendation |
|---|---|
| Starting dose | 4.5 g IV every 8 hours (if renal function normal) |
| Titration | Not applicable |
| Renal consideration | Calculate CrCl; age-related decline in renal function common even with normal serum creatinine; dose reduce per renal adjustment table |
| Specific risks | Increased susceptibility to nephrotoxicity, electrolyte disturbances (hypokalaemia), bleeding, and confusion/encephalopathy at higher doses |
| Monitoring | Renal function before and during therapy; electrolytes; signs of neurotoxicity |
Major drug interactions
| Drug | Interaction | Recommendation |
|---|---|---|
| Methotrexate | Reduced renal clearance of methotrexate → increased risk of haematological and GI toxicity | AVOID combination if possible; if essential, monitor methotrexate levels and CBC closely; consider leucovorin rescue |
| Probenecid | Inhibits tubular secretion → increased and prolonged piperacillin levels | Avoid concurrent use; if used together, monitor for toxicity |
| Neuromuscular blocking agents (Vecuronium, Rocuronium, Atracurium) | Prolonged neuromuscular blockade reported with aminopenicillins | Monitor neuromuscular function closely; may require dose adjustment of paralytic agent |
| Oral anticoagulants (Warfarin, Acenocoumarol) | Enhanced anticoagulant effect; mechanism includes vitamin K suppression via gut flora alteration | Monitor INR closely during and after Pip-Tazo course; adjust anticoagulant dose as needed |
Moderate drug interactions
| Drug | Interaction | Recommendation |
|---|---|---|
| Aminoglycosides (Amikacin, Gentamicin, Tobramycin) | Synergistic antibacterial effect but physical incompatibility if mixed; additive nephrotoxicity | Administer via separate IV lines; never mix in same bag; monitor renal function and aminoglycoside levels |
| Vancomycin | Increased risk of acute kidney injury when used in combination | Unidentified |
| Loop diuretics (Furosemide) | Potential increased nephrotoxicity | Monitor renal function; generally safe with hydration |
| Heparin | Potential additive effect on bleeding time | Monitor for bleeding; use standard coagulation monitoring |
| Phenytoin | Possible decreased phenytoin levels | Monitor phenytoin levels if used concurrently |
Common Adverse effects
- Diarrhoea (most frequent)
- Nausea and vomiting
- Skin rash (maculopapular)
- Injection site reactions (phlebitis, pain)
- Headache
- Insomnia
- Hypokalaemia
- Transient elevation of liver enzymes (AST, ALT)
- Fever
- Positive direct Coombs test (without haemolysis)
Serious Adverse effects
| Adverse Effect | Clinical Notes |
|---|---|
| Anaphylaxis | Rare; discontinue immediately; manage with adrenaline and supportive care |
| Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis | Very rare; discontinue immediately; requires hospitalisation |
| Clostridioides difficile-associated diarrhoea (CDAD) | May occur during or after therapy; discontinue Pip-Tazo if confirmed; treat with oral vancomycin or fidaxomicin |
| Acute interstitial nephritis | Presents with fever, rash, eosinophilia, rising creatinine; discontinue and consider corticosteroids |
| Haematological toxicity (Thrombocytopenia, Leucopenia, Neutropenia) | Usually with prolonged therapy (>14 days); monitor CBC weekly; typically reversible on discontinuation |
| Seizures | Risk increased with high doses, renal impairment, or pre-existing CNS disease; ensure appropriate dose adjustment |
| Coagulopathy | Vitamin K-dependent; more common with prolonged use or malnutrition; monitor PT/INR |
| Drug-induced liver injury | Rare; cholestatic pattern; monitor LFTs if symptomatic |
Monitoring requirements
| Phase | Parameters |
|---|---|
| Baseline | Serum creatinine, eGFR/CrCl, LFTs, CBC with differential, electrolytes (especially potassium), allergy history |
| During treatment (short course <7 days) | Renal function (every 2–3 days in ICU/high-risk patients); clinical response; signs of hypersensitivity |
| During treatment (≥7 days) | CBC weekly; LFTs weekly; renal function every 2–3 days; electrolytes (K+) |
| Prolonged therapy (>14 days) | As above + coagulation profile (PT/INR); watch for superinfection (oral thrush, C. difficile); neurotoxicity signs |
| If on concomitant nephrotoxins | Renal function daily or alternate days |
Brands in India
| Brand Name | Manufacturer |
|---|---|
| Tazact | Cipla |
| Pipzo | Dr. Reddy's |
| Zosyn | Pfizer |
| Piptaz | Aristo |
| Tazopen | Alkem |
| Pipracil Plus | Lupin |
| Tazofast | Hetero |
| Piperacillin + Tazobactam (Generic) | Multiple manufacturers |
Government/Jan Aushadhi Supply: Available under generic names at subsidised rates
Price range (INR)
| Formulation | Approximate Price |
|---|---|
| 4.5 g vial (Private brands) | ₹150–₹350 |
| 4.5 g vial (Jan Aushadhi/Government supply) | ₹50–₹100 |
| 2.25 g vial (Private brands) | ₹80–₹180 |
| 2.25 g vial (Jan Aushadhi/Government supply) | ₹30–₹60 |
Regulatory Note: Listed under NLEM 2022. NPPA price-controlled for scheduled formulations. Available through government hospital pharmacies and Jan Aushadhi kendras.
Clinical pearls
- Extended infusion strategy: For severe infections (sepsis, VAP, febrile neutropenia), administer each dose over 3–4 hours instead of standard 30 minutes. This optimises time above MIC and improves pharmacodynamic outcomes. Widely adopted in Indian ICUs.
- Spectrum limitations: Pip-Tazo does NOT cover MRSA, VRE, carbapenem-resistant Enterobacteriaceae (CRE), or Stenotrophomonas maltophilia. Add appropriate agents if these are suspected.
- ESBL coverage caveat: Effective against many ESBL-producing organisms, but MIC creep reported. Use only if local antibiogram shows susceptibility >90%. Carbapenems preferred for serious ESBL infections with sepsis.
- Sodium load awareness: Each 4.5 g vial contains ~9.4 mEq sodium. In patients receiving every-6-hour dosing, daily sodium from Pip-Tazo alone exceeds 37 mEq. Adjust total sodium intake in heart failure and cirrhosis.
- De-escalation imperative: Pip-Tazo is a broad-spectrum reserve antibiotic. Always review cultures at 48–72 hours and de-escalate to narrower-spectrum agent when susceptibilities available. This aligns with ICMR AMR stewardship recommendations.
- Vancomycin combination nephrotoxicity: Recent evidence shows increased AKI risk with Pip-Tazo + Vancomycin compared to other beta-lactam + vancomycin combinations. Use with close renal monitoring and consider alternatives if renal function declines.
Version
RxIndia v1.0 — 30 Apr 2025
Reference
- CDSCO Drug Database and Product Inserts
- Indian Pharmacopoeia 2022
- National List of Essential Medicines (NLEM) 2022
- API Textbook of Medicine (11th Edition)
- AIIMS Antimicrobial Guidelines 2022
- ICMR Treatment Guidelines for Antimicrobial Use in Common Syndromes (2019)
- ICMR Antimicrobial Resistance Surveillance Network Reports
- Tata Memorial Hospital Febrile Neutropenia Protocols
- IAP Guidelines for Paediatric Antimicrobial Use
- Harrison's Principles of Internal Medicine (21st Edition)
- Goodman & Gilman's The Pharmacological Basis of Therapeutics
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.